{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:04:20Z","timestamp":1789268660128,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Ministerio de Econom\u00eda y Competitividad, Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Funds-European Union","doi-asserted-by":"publisher","award":["RD12\/0028\/0001"],"award-info":[{"award-number":["RD12\/0028\/0001"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Funds-European Union","doi-asserted-by":"publisher","award":["RD16\/0017\/0001"],"award-info":[{"award-number":["RD16\/0017\/0001"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Funds-European Union","doi-asserted-by":"publisher","award":["PI16\/01953"],"award-info":[{"award-number":["PI16\/01953"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Funds-European Union","doi-asserted-by":"publisher","award":["PI16\/01689"],"award-info":[{"award-number":["PI16\/01689"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Funds-European Union","doi-asserted-by":"publisher","award":["PI17\/02026"],"award-info":[{"award-number":["PI17\/02026"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Asuntos Sociales e Igualdad and Plan Nacional sobre Drogas","doi-asserted-by":"publisher","award":["PND2015\/047"],"award-info":[{"award-number":["PND2015\/047"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003751","name":"Ministerio de Sanidad, Asuntos Sociales e Igualdad and Plan Nacional sobre Drogas","doi-asserted-by":"publisher","award":["PND2017\/043"],"award-info":[{"award-number":["PND2017\/043"]}],"id":[{"id":"10.13039\/501100003751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Junta de Andaluc\u00eda, Plan Andaluz de Investigaci\u00f3n, Desarrollo e Innovaci\u00f3n"},{"DOI":"10.13039\/501100008530","name":"ERDF-EU","doi-asserted-by":"publisher","award":["PAIDI CTS-433"],"award-info":[{"award-number":["PAIDI CTS-433"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2014SGR 680"],"award-info":[{"award-number":["2014SGR 680"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Spanish Ministry of Science, Innovation and Universities","doi-asserted-by":"publisher","award":["CAS18\/00263"],"award-info":[{"award-number":["CAS18\/00263"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga Incorporaci\u00f3n a Doctores, Plan Propio","doi-asserted-by":"publisher","award":["CI-17-415"],"award-info":[{"award-number":["CI-17-415"]}],"id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Bienestar Social, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["EF-2020-2017"],"award-info":[{"award-number":["EF-2020-2017"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"ISCIII","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF-EU","doi-asserted-by":"publisher","award":["CPII17\/00024"],"award-info":[{"award-number":["CPII17\/00024"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF-EU","doi-asserted-by":"publisher","award":["CP14\/00212"],"award-info":[{"award-number":["CP14\/00212"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"ERDF-EU","doi-asserted-by":"publisher","award":["CP14\/00173"],"award-info":[{"award-number":["CP14\/00173"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.neuropharm.2019.02.026","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T16:12:44Z","timestamp":1551197564000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-3835","authenticated-orcid":false,"given":"Pablo","family":"Romero-Sanchiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Nogueira-Arjona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Araos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Boronat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Garcia-Marchena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermin","family":"Mayoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bordallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Alen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5254-9802","authenticated-orcid":false,"given":"Juan","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5256-8904","authenticated-orcid":false,"given":"Francisco J.","family":"Pav\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-5795","authenticated-orcid":false,"given":"Fernando","family":"Rodr\u00edguez de Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.02.026_bib1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/adb.12365","article-title":"Oleoylethanolamide prevents neuroimmune HMGB1\/TLR4\/NF-kB danger signaling in rat frontal cortex and depressive-like behavior induced by ethanol binge administration","volume":"22","author":"Ant\u00f3n","year":"2017","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib2","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1111\/bph.14501","article-title":"Alcohol binge disrupts the rat intestinal barrier: the partial protective role of oleoylethanolamide","volume":"175","author":"Ant\u00f3n","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck depression inventories -IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib4","volume":"vol. 1","author":"Beck","year":"1996"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/adb.12006","article-title":"Oleoylethanolamide dose-dependently attenuates cocaine-induced behaviours through a PPAR\u03b1 receptor-independent mechanism","volume":"18","author":"Bilbao","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/adb.12276","article-title":"Role of the satiety factor oleoylethanolamide in alcoholism","volume":"21","author":"Bilbao","year":"2016","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/pr.112.006387","article-title":"Chemical probes of endocannabinoid metabolism","volume":"65","author":"Blankman","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","article-title":"Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress","volume":"62","author":"Bortolato","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.mehy.2013.12.016","article-title":"Is there a role for palmitoylethanolamide in the treatment of depression?","volume":"82","author":"Coppola","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuropharm.2018.03.033","article-title":"Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide","volume":"135","author":"Costa","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib11","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Clinician Version (SCID-CV)","author":"First","year":"1997"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature01921","article-title":"Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha","volume":"425","author":"Fu","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib13","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1523\/JNEUROSCI.0036-10.2010","article-title":"The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin","volume":"30","author":"Gaetani","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neubiorev.2008.03.004","article-title":"Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders","volume":"32","author":"Gorzalka","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib15","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.4088\/JCP.v64n1211","article-title":"The economic burden of depression in the United States: how did it change between 1990 and 2000?","volume":"64","author":"Greenberg","year":"2003","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2009.06.006","article-title":"The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants","volume":"30","author":"Hill","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.psyneuen.2009.03.013","article-title":"Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress","volume":"34","author":"Hill","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib19","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.2174\/13816128113196660735","article-title":"Endocannabinoid signaling in the etiology and treatment of major depressive illness","volume":"20","author":"Hillard","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bph.13668","article-title":"Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway","volume":"174","author":"Jiang","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pbb.2015.04.001","article-title":"Antidepressant-like effects of oleoylethanolamide in a mouse model of chronic unpredictable mild stress","volume":"133","author":"Jin","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib22","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","article-title":"Modulation of anxiety through blockade of anandamide hydrolysis","volume":"9","author":"Kathuria","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib23","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib25","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1177\/0269881112454229","article-title":"Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes","volume":"26","author":"Mitjans","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00213-013-2995-y","article-title":"Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment","volume":"227","author":"Mitjans","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.phrs.2010.01.002","article-title":"Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression","volume":"61","author":"Monteleone","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib28","doi-asserted-by":"crossref","first-page":"pyv045","DOI":"10.1093\/ijnp\/pyv045","article-title":"Brain histamine is crucial for selective serotonin reuptake inhibitors' behavioral and neurochemical effects","volume":"18","author":"Munari","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001756-199701200-00023","article-title":"Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat","volume":"8","author":"Navarro","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1194\/jlr.D043794","article-title":"Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs","volume":"55","author":"Pastor","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/adb.12107","article-title":"Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity","volume":"18","author":"Pav\u00f3n","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib32","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/syn.20733","article-title":"Effects of the endogenous PPAR-\u00ce\u00b1 agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice","volume":"64","author":"Plaza-Zabala","year":"2010","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib34","doi-asserted-by":"crossref","first-page":"11527","DOI":"10.1073\/pnas.1322016111","article-title":"Satiety factor oleoylethanolamide recruits the brain histaminergic system to inhibit food intake","volume":"111","author":"Provensi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cpr.2011.07.004","article-title":"Prevalence and clinical course of depression: a review","volume":"31","author":"Richards","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/35102582","article-title":"An anorexic lipid mediator regulated by feeding","volume":"414","author":"Rodr\u00edguez de Fonseca","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-319-20825-1_9","article-title":"Endocannabinoids and mental disorders","volume":"31","author":"Rubino","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib38","article-title":"Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats","volume":"18","author":"Sayd","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eurpsy.2014.08.007","article-title":"Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression: an open trial","volume":"30","author":"Scantamburlo","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib40","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1098\/rstb.2012.0313","article-title":"Endocannabinoids in nervous system health and disease: the big picture in a nutshell","volume":"367","author":"Skaper","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1037\/a0035302","article-title":"From stress to inflammation and major depressive disorder: a social signal transduction theory of depression","volume":"140","author":"Slavich","year":"2014","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12640-014-9465-0","article-title":"Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures","volume":"26","author":"Smaga","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib43","first-page":"87","article-title":"Cost of depression in europe","volume":"9","author":"Sobocki","year":"2006","journal-title":"J. Ment. Health Pol. Econ."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib44","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1111\/bph.14346","article-title":"Hippocampal PPAR\u03b1 is a novel therapeutic target for depression and mediates the antidepressant actions of fluoxetine in mice","volume":"175","author":"Song","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib45","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.1239275","article-title":"A gut lipid messenger links excess dietary fat to dopamine deficiency","volume":"341","author":"Tellez","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002130050867","article-title":"Oxytocin as a possible mediator of SSRI-induced antidepressant effects","volume":"142","author":"Uvn\u00e4s-Moberg","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.02.026_bib47","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.tins.2017.04.005","article-title":"Endocannabinoid signaling in the control of social behavior","volume":"40","author":"Wei","year":"2017","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2015.03.019","article-title":"Involvement of norepinephrine and serotonin system in antidepressant-like effects of oleoylethanolamide in the mice models of behavior despair","volume":"593","author":"Yu","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.02.026_bib49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/pgs.14.40","article-title":"Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response","volume":"15","author":"Zajkowska","year":"2014","journal-title":"Pharmacogenomics"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:05:01Z","timestamp":1595988301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819300590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"alternative-id":["S0028390819300590"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.026","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}